A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System

References

• Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. doi:10.1136/bmj.m3773
   PubMed Web of Science ®Google Scholar
• Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156. doi:10.1016/j.soncn.2019.02.001
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505. doi:10.1056/NEJMoa1810858
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917. doi:10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(1):77–102. doi:10.6004/jnccn.2021.0001
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158. doi:10.1126/science.aam7344
   PubMed Web of Science ®Google Scholar
• Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345–2357. doi:10.1056/NEJMoa2022485
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566. doi:10.1093/annonc/mdz012
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMoa1903387
   PubMed Web of Science ®Google Scholar
• Ruiz-Schutz VC, Gomes LM, Mariano RC, et al. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2019;141:163–173. doi:10.1016/j.critrevonc.2019.06.012
   PubMed Web of Science ®Google Scholar
• Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther. 2018;12:3013–3019. doi:10.2147/DDDT.S164553
   PubMed Web of Science ®Google Scholar
• Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2017;11:3009–3017. doi:10.2147/DDDT.S147726
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. doi:10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15(5):583–590. doi:10.1517/14740338.2016.1167184
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Dai B, Zhang Q. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022;21(4):563–572. doi:10.1080/14740338.2022.2016696
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–250. doi:10.1200/JCO.2014.56.2728
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Penson RT, Domchek SM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016;27(6):1013–1019. doi:10.1093/annonc/mdw133
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284. doi:10.1016/S1470-2045(17)30469-2
   PubMed Web of Science ®Google Scholar
• Shammo JM, Usha L, Richardson KJ, et al. Olaparib-induced severe folate deficiency in a patient with advanced ovarian cancer. J Oncol Pract. 2019;15(7):405–407. doi:10.1200/JOP.18.00705
   Web of Science ®Google Scholar
• Shenolikar R, Durden E, Meyer N, Lenhart G, Moore K. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol. 2018;151(2):190–195. doi:10.1016/j.ygyno.2018.09.003
   PubMed Web of Science ®Google Scholar
• Hopkins TA, Ainsworth WB, Ellis PA, et al. PARP1 trapping by parp inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol Cancer Res. 2019;17(2):409–419. doi:10.1158/1541-7786.MCR-18-0138
   PubMed Web of Science ®Google Scholar
• Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M. Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: bridging Formulations, Drug Interactions, and Patient Populations. Clin Pharmacol Ther. 2019;105(1):229–241. doi:10.1002/cpt.1103
   PubMed Web of Science ®Google Scholar
• Bruin MAC, Korse CM, van Wijnen B, et al. A real or apparent decrease in glomerular filtration rate in patients using olaparib? Eur J Clin Pharmacol. 2021;77(2):179–188. doi:10.1007/s00228-020-03070-0
   PubMed Web of Science ®Google Scholar
• Karam SD, Reddy K, Blatchford PJ, et al. Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer. Clin Cancer Res. 2018;24(20):4949–4959. doi:10.1158/1078-0432.CCR-18-0467
   PubMed Web of Science ®Google Scholar
• Ngu SF, Tse KY, Chu MMY, Ngan HYS, Chan KKL. Olaparib dose re-escalation in ovarian cancer patients who experienced severe and/or uncommon adverse events: a case series. Asia Pac J Clin Oncol. 2021;17(Suppl 3):3–11. doi:10.1111/ajco.13584
   Web of Science ®Google Scholar
• Del Conte G, Sessa C, von Moos R, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 2014;111(4):651–659. doi:10.1038/bjc.2014.345
   PubMed Web of Science ®Google Scholar
• Ma Z, Sun X, Zhao Z, et al. Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecol Oncol. 2021;162(2):496–505. doi:10.1016/j.ygyno.2021.05.012
   PubMed Web of Science ®Google Scholar
• Bai P. Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell. 2015;58(6):947–958. doi:10.1016/j.molcel.2015.01.034
   PubMed Web of Science ®Google Scholar
• Dharwal V, Naura AS. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice. Biochem Pharmacol. 2018;150:24–34. doi:10.1016/j.bcp.2018.01.027
   PubMed Web of Science ®Google Scholar
• Sethi GS, Sharma S, Naura AS. PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice. IUBMB Life. 2019;71(7):1003–1013. doi:10.1002/iub.2048
   PubMed Web of Science ®Google Scholar